NASD · Healthcare · Biotechnology · United Kingdom
Bicycle Therapeutics Plc ADR is a micro cap company (market value under $300 million) in the Biotechnology industry.
Bicycle Therapeutics discovers and develops medicines based on Bicycle molecules, fully synthetic constrained peptides, primarily for oncology. The company employs a proprietary phage display screening platform to identify these molecules, which combine properties of biologic drugs with small molecule manufacturing advantages. Its lead candidates include nuzefatide pevedotin targeting EphA2 and BT1702 targeting MT1-MMP, with additional collaborations in other disease areas.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bicycle Therapeutics Plc ADR stock.
Undervalued: intrinsic value $12.70 per share, market price $3.66, margin of safety 71.2% (as of 2026-10-30).
A 2.4x revenue multiple, discounted for its losses, values the shares at $12.70; the price of $3.66 is 71% below that value.
Leak Score: 56/100 on 8 of 12 signals (Weak Signal).
BCYC is undervalued (as of the 2026-10-30 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $12.70; the price of $3.66 is 71% below that value.
$12.70 per share (as of the 2026-10-30 close), against a market price of $3.66. That is a margin of safety of 71.2%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
56 out of 100, which we rate "Weak Signal", on 8 of 12 value investing signals.